|
Stories from the dialysis comunity across the globe.
|
|
Nuts ! |
 |
 |
|
NEJM: Conclusions. In two large, independent cohorts of nurses and other health professionals, the frequency of nut consumption was inversely associated with total and cause-specific mortality, independently of other predictors of death.
|
|
|
New study of spironolactone in heart failure fails to show improvement in many hard outcomes. |
|
|
|
Brigham and Womens Hospital: Boston, MA - A late-breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, to be presented at the American Heart Association (AHA) Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function). However, spironolactone did reduce the major burden faced by these patients-the risk of repeated hospitalizations for heart failure.
|
|
Advanced CT imaging as good as angiography to detect CAD blockages. |
|
|
|
EurekAlert: "We found that the 320-detector CT scanner allowed us to see the anatomy of the blockages and determine whether the blockages were causing a lack of perfusion to the heart," sayslead author Carlos E. Rochitte, M.D., a cardiologist at the Heart Institute (InCor), University of Sao Paulo Medical School, in Brazil, "We were therefore able to correctly identify the patients who needed revascularization within 30 days of their evaluation."
|
|
|
Gene therapy shows long-lasting benefits in patients with heart failure. |
|
|
|
EurekAlert: The new long-term follow-up results from their initial Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID 1) clinical trial found a one-time, high-dose injection of the AAV1/SERCA2a gene therapy results in the presence of the delivered SERCA2a gene up to 31 months in the cardiac tissue of heart failure patients. In addition, study results show clinical event rates in gene therapy patients are significantly lower three years later compared to those patients receiving placebo. Also, patients experienced no negative side effects following gene therapy delivery at three-year follow-up.
|
|
Aldehyde compound stimulates UC-1 to burn body fat. |
|
|
|
Vienna U. of Veterinary Medicine: A research team at the University of Veterinary Medicine (Vetmeduni Vienna) has found that a specific chemical compound, an aldehyde, can activate UCP1 under certain conditions, and that could also trigger fat burning. The data were published in the Journal Plos One.
|
|
|
|
|
<< Start < Prev 411 412 413 414 415 416 417 418 419 420 Next > End >>
|
|
Page 420 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
